1
|
Ribrag V, Davar D, Garralda E, Curigliano G, Zain J, Mehta A, Minchom A, Sanborn R, Foss F, Oberoi H, Forero-Torres A, Ansell S. 558TiP Phase I study of effector-function enhanced monoclonal antibody (mAb), SEA-TGT, in advanced malignancies. Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.08.1080] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
2
|
Diefenbach C, Hong F, Ambinder R, Cohen J, Robertson M, David K, Advani R, Fenske T, Barta S, Palmisano N, Svoboda J, Morgan D, Karmali R, Kahl B, Ansell S. EXTENDED FOLLOW-UP OF A PHASE I TRIAL OF IPILIMUMAB, NIVOLUMAB AND BRENTUXIMAB VEDOTIN IN RELAPSED HODGKIN LYMPHOMA: A TRIAL OF THE ECOG-ACRIN RESEARCH GROUP (E4412). Hematol Oncol 2019. [DOI: 10.1002/hon.83_2629] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Affiliation(s)
- C.S. Diefenbach
- Hematology-Oncology; Perlmutter Cancer Center at NYU Langone Health; New York United States
| | - F. Hong
- ECOG-ACRIN Biostatistics Center; Dana Farber Cancer Institute; Boston United States
| | - R. Ambinder
- Sidney Kimmel Cancer Center; Johns Hopkins University; Baltimore MD United States
| | - J. Cohen
- Winship Cancer Institute; Emory University; Atlanta United States
| | - M. Robertson
- Hematology-Oncology; Indiana Unversity School of Medicine; Indianapolis United States
| | - K. David
- Hematology-Oncology; Rutgers Cancer Institute of New Jersey; New Brunswick United States
| | - R. Advani
- Oncology; Stanford Cancer Institute; San Francisco United States
| | - T. Fenske
- Hematology-Oncology; Froedtert and the Medical College of Wisconsin; Milwaukee United States
| | - S. Barta
- Abramson Cancer Center; University of Pennsylvania; Philadelphia United States
| | - N. Palmisano
- Hematology-Oncology; Thomas Jefferson University Hospital; Philadelphia United States
| | - J. Svoboda
- Abramson Cancer Center; University of Pennsylvania; Philadelphia United States
| | - D. Morgan
- Hematology-Oncology; Vanderbilt Ingram Henry Cancer Center; Nashville United States
| | - R. Karmali
- Feinberg School of Medicine; Northwestern University; Chicago United States
| | - B. Kahl
- Oncology; Washington University School of Medicine; St. Louis United States
| | - S. Ansell
- Hematology-Oncology; Mayo Clinic; Rochester United States
| |
Collapse
|
3
|
Lunning M, Horwitz S, Advani R, Vose J, Lee H, Mehta-Shah N, Zain J, Haverkos B, Lechowicz M, Moskowitz A, Heires P, Lyden L, Ansell S. PHASE I/II STUDY OF CHOEP PLUS LENALIDOMIDE AS INITIAL THERAPY FOR PATIENTS WITH STAGE II-IV PERIPHERAL T-CELL LYMPHOMA: PHASE II RESULTS. Hematol Oncol 2019. [DOI: 10.1002/hon.91_2630] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Affiliation(s)
- M. Lunning
- Hematology/Oncology; University of Nebraska Medical Center; Omaha United States
| | - S. Horwitz
- Lymphoma Service; Memorial Sloan Kettering Cancer Center; New York United States
| | - R. Advani
- Lymphoma Program; Stanford University; Palo Alto United States
| | - J. Vose
- Hematology/Oncology; University of Nebraska Medical Center; Omaha United States
| | - H. Lee
- Lymphoma & Myeloma; MD Anderson Cancer Center; Houston United States
| | - N. Mehta-Shah
- Oncology; Washington University; St. Louis United States
| | - J. Zain
- Hematology & Hematopoetic Cell Transplantation; City of Hope; Duarte United States
| | - B. Haverkos
- Oncology; University of Colorado; Aurora United States
| | - M. Lechowicz
- Hematology/Oncology; Emory; Atlanta United States
| | - A. Moskowitz
- Lymphoma Service; Memorial Sloan Kettering Cancer Center; New York United States
| | - P. Heires
- Hematology/Oncology; University of Nebraska Medical Center; Omaha United States
| | - L. Lyden
- Hematology/Oncology; University of Nebraska Medical Center; Omaha United States
| | - S. Ansell
- Lymphoma; Mayo Clinic; Rochester United States
| |
Collapse
|
4
|
Topp M, Arnason J, Advani R, Brown J, Allan J, Ansell S, O'Brien S, Chavez J, Duell J, Rosenwald A, Charnas R, Ambati S, Adriaens L, Ufkin M, Zhu M, Li J, Gasparini P, Jankovic V, Fiaschi N, Zhang W, Hamon S, Thurston G, Murphy A, Yancopoulos G, Lowy I, Sternberg D, Bannerji R. CLINICAL ACTIVITY OF REGN1979, AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY (AB) IN PATIENTS (PTS) WITH (W/) RELAPSED/REFRACTORY (R/R) B-CELL NON-HODGKIN LYMPHOMA (B-NHL). Hematol Oncol 2019. [DOI: 10.1002/hon.58_2629] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Affiliation(s)
- M.S. Topp
- Department of Internal Medicine; Universitätsklinikum Würzburg; Würzburg Germany
| | - J. Arnason
- Hematology/Oncology Division; Beth Israel Deaconess Medical Center; Boston United States
| | - R. Advani
- Department of Medicine; Stanford University; Stanford United States
| | - J.R. Brown
- Center for Hematologic Oncology; Dana-Farber Cancer Institute; Boston United States
| | - J. Allan
- Division of Hematology and Medical Oncology; Weill Cornell Medicine; New York United States
| | - S. Ansell
- Department of Internal Medicine; Mayo Clinic; Rochester United States
| | - S. O'Brien
- Division of Hematology/Oncology; University of California; Irvine United States
| | - J. Chavez
- Department of Oncologic Sciences; Moffitt Cancer Center; Tampa United States
| | - J. Duell
- Department of Internal Medicine; Universitätsklinikum Würzburg; Würzburg Germany
| | - A. Rosenwald
- Institute of Pathology; University of Würzburg; Würzburg Germany
| | - R. Charnas
- Hematology/Oncology; Regeneron Pharmaceuticals, Inc.; Tarrytown United States
| | - S.R. Ambati
- Hematology/Oncology; Regeneron Pharmaceuticals, Inc.; Tarrytown United States
| | - L. Adriaens
- Hematology/Oncology; Regeneron Pharmaceuticals, Inc.; Basking Ridge United States
| | - M. Ufkin
- Hematology/Oncology; Regeneron Pharmaceuticals, Inc.; Tarrytown United States
| | - M. Zhu
- Hematology/Oncology; Regeneron Pharmaceuticals, Inc.; Tarrytown United States
| | - J. Li
- Hematology/Oncology; Regeneron Pharmaceuticals, Inc.; Basking Ridge United States
| | - P. Gasparini
- Hematology/Oncology; Regeneron Pharmaceuticals, Inc.; Tarrytown United States
| | - V. Jankovic
- Hematology/Oncology; Regeneron Pharmaceuticals, Inc.; Tarrytown United States
| | - N. Fiaschi
- Hematology/Oncology; Regeneron Pharmaceuticals, Inc.; Tarrytown United States
| | - W. Zhang
- Hematology/Oncology; Regeneron Pharmaceuticals, Inc.; Tarrytown United States
| | - S. Hamon
- Hematology/Oncology; Regeneron Pharmaceuticals, Inc.; Tarrytown United States
| | - G. Thurston
- Hematology/Oncology; Regeneron Pharmaceuticals, Inc.; Tarrytown United States
| | - A.J. Murphy
- Hematology/Oncology; Regeneron Pharmaceuticals, Inc.; Tarrytown United States
| | - G.D. Yancopoulos
- Hematology/Oncology; Regeneron Pharmaceuticals, Inc.; Tarrytown United States
| | - I. Lowy
- Hematology/Oncology; Regeneron Pharmaceuticals, Inc.; Tarrytown United States
| | - D. Sternberg
- Hematology/Oncology; Regeneron Pharmaceuticals, Inc.; Tarrytown United States
| | - R. Bannerji
- Section of Hematologic Malignancies; Rutgers Cancer Institute of New Jersey; New Brunswick United States
| |
Collapse
|
5
|
Ansell S, Ramchandren R, Domingo-Domènech E, Rueda A, Trněný M, Feldman T, Lee H, Provencio M, Sillaber C, Cohen J, Savage K, Willenbacher W, Sumbul A, Sacchi M, Armand P. NIVOLUMAB PLUS DOXORUBICIN, VINBLASTINE AND DACARBAZINE FOR NEWLY DIAGNOSED ADVANCED-STAGE CLASSICAL HODGKIN LYMPHOMA: CHECKMATE 205 COHORT D 2-YEAR FOLLOW-UP. Hematol Oncol 2019. [DOI: 10.1002/hon.104_2629] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Affiliation(s)
- S. Ansell
- Division of Hematology; Mayo Clinic; Rochester United States
| | - R. Ramchandren
- Division of Hematology and Oncology; University of Tennessee; Knoxville United States
| | | | - A. Rueda
- Servicio de Oncología; Hospital Costa del Sol; Marbella Spain
| | - M. Trněný
- Department of Haematology; Charles University in Prague and General University Hospital in Prague; Prague Czech Republic
| | - T. Feldman
- Hematology & Oncology; Hackensack University Medical Center; Hackensack United States
| | - H. Lee
- Department of Lymphoma and Myeloma; Division of Cancer Medicine, University of Texas MD Anderson Cancer Center; Houston United States
| | - M. Provencio
- Medical Oncology Department; Hospital Universitario Puerta de Hierro; Madrid Spain
| | - C. Sillaber
- Clinical Division of Oncology; Medical University of Vienna; Vienna Austria
| | - J. Cohen
- Department of Hematology and Medical Oncology; Winship Cancer Institute, Emory University; Atlanta United States
| | - K. Savage
- Department of Pathology and Laboratory Medicine; British Columbia Cancer Center for Lymphoid Cancer; Vancouver Canada
| | - W. Willenbacher
- Department of Internal Medicine; Innsbruck University Hospital & OncoTyrol - Center for Personalized Cancer Medicine; Innsbruck Austria
| | - A. Sumbul
- Bristol-Myers Squibb; Princeton United States
| | - M. Sacchi
- Bristol-Myers Squibb; Princeton United States
| | - P. Armand
- Department of Medical Oncology; Dana-Farber Cancer Institute; Boston United States
| |
Collapse
|
6
|
Castillo J, Itchaki G, Paludo J, Varettoni M, Buske C, Eyre T, Chavez J, Shain K, Issa S, Palomba L, Pasvolsky O, Simpson D, Talaulikar D, Tam C, Tedeschi A, Ansell S, Nayak L, Treon S. IBRUTINIB FOR THE TREATMENT OF BING-NEEL SYNDROME: A RETROSPECTIVE, MULTICENTER STUDY. Hematol Oncol 2019. [DOI: 10.1002/hon.140_2629] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Affiliation(s)
- J. Castillo
- Bing Center for Waldenstrom Macroglobulinemia; Dana-Farber Cancer Institute; Boston United States
| | - G. Itchaki
- Hematology; Rabin Medical Center; Petah Tikva Israel
| | - J. Paludo
- Hematology and Oncology; Mayo Clinic; Rochester United States
| | - M. Varettoni
- Hematology; Fondazione IRCCS Policlinico San Matteo; Pavia Italy
| | - C. Buske
- Comprehensive Cancer Center; University Hospital Ulm; Ulm Germany
| | - T. Eyre
- Hematology; Churchill Hospital; Oxford United Kingdom
| | - J. Chavez
- Malignant Hematology; Moffitt Cancer Institute; Tampa United States
| | - K. Shain
- Malignant Hematology; Moffitt Cancer Institute; Tampa United States
| | - S. Issa
- Hematology; Middlemore Hospital; Auckland New Zealand
| | - L. Palomba
- Hematology and Oncology; Memorial Sloan Kettering Cancer Center; New York United States
| | - O. Pasvolsky
- Hematology; Rabin Medical Center; Petah Tikva Israel
| | - D. Simpson
- Hematology; North Shore Hospital; Auckland New Zealand
| | | | - C. Tam
- Hematology; Peter MacCallum Cancer Centre; Melbourne Australia
| | | | - S. Ansell
- Hematology and Oncology; Mayo Clinic; Rochester United States
| | - L. Nayak
- Center for CNS Lymphoma; Dana-Farber Cancer Institute; Boston United States
| | - S. Treon
- Bing Center for Waldenstrom Macroglobulinemia; Dana-Farber Cancer Institute; Boston United States
| |
Collapse
|
7
|
Kumar E, Korfi K, Bewicke-Copley F, Witzig T, Leukam M, Ansell S, Scott J, Rallis K, Clear A, Efeyan A, Calaminici M, Wang J, Okosun J, Smith S, Novak A, Fitzgibbon J. MUTATIONS AFFECTING THE CREBBP HAT DOMAIN PREDICT RESPONSE TO MTOR INHIBITORS EVEROLIMUS AND TEMSIROLIMUS IN RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA. Hemasphere 2019. [DOI: 10.1097/02014419-201906001-00412] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
|
8
|
Kumar E, Korfi K, Bewicke-Copley F, Witzig T, Leukam M, Ansell S, Scott J, Rallis K, Clear A, Efeyan A, Calaminici M, Wang J, Okosun J, Smith S, Novak A, Fitzgibbon J. PF513 MUTATIONS AFFECTING THE CREBBP HAT DOMAIN PREDICT RESPONSE TO MTOR INHIBITORS EVEROLIMUS AND TEMSIROLIMUS IN RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA. Hemasphere 2019. [DOI: 10.1097/01.hs9.0000560152.86937.ed] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
|
9
|
Younes A, Hilden P, Coiffier B, Hagenbeek A, Salles G, Wilson W, Seymour JF, Kelly K, Gribben J, Pfreunschuh M, Morschhauser F, Schoder H, Zelenetz AD, Rademaker J, Advani R, Valente N, Fortpied C, Witzig TE, Sehn LH, Engert A, Fisher RI, Zinzani PL, Federico M, Hutchings M, Bollard C, Trneny M, Elsayed YA, Tobinai K, Abramson JS, Fowler N, Goy A, Smith M, Ansell S, Kuruvilla J, Dreyling M, Thieblemont C, Little RF, Aurer I, Van Oers MHJ, Takeshita K, Gopal A, Rule S, de Vos S, Kloos I, Kaminski MS, Meignan M, Schwartz LH, Leonard JP, Schuster SJ, Seshan VE. International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017). Ann Oncol 2017; 28:1436-1447. [PMID: 28379322 PMCID: PMC5834038 DOI: 10.1093/annonc/mdx097] [Citation(s) in RCA: 200] [Impact Index Per Article: 28.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/24/2017] [Indexed: 12/20/2022] Open
Abstract
In recent years, the number of approved and investigational agents that can be safely administered for the treatment of lymphoma patients for a prolonged period of time has substantially increased. Many of these novel agents are evaluated in early-phase clinical trials in patients with a wide range of malignancies, including solid tumors and lymphoma. Furthermore, with the advances in genome sequencing, new "basket" clinical trial designs have emerged that select patients based on the presence of specific genetic alterations across different types of solid tumors and lymphoma. The standard response criteria currently in use for lymphoma are the Lugano Criteria which are based on [18F]2-fluoro-2-deoxy-D-glucose positron emission tomography or bidimensional tumor measurements on computerized tomography scans. These differ from the RECIST criteria used in solid tumors, which use unidimensional measurements. The RECIL group hypothesized that single-dimension measurement could be used to assess response to therapy in lymphoma patients, producing results similar to the standard criteria. We tested this hypothesis by analyzing 47 828 imaging measurements from 2983 individual adult and pediatric lymphoma patients enrolled on 10 multicenter clinical trials and developed new lymphoma response criteria (RECIL 2017). We demonstrate that assessment of tumor burden in lymphoma clinical trials can use the sum of longest diameters of a maximum of three target lesions. Furthermore, we introduced a new provisional category of a minor response. We also clarified response assessment in patients receiving novel immune therapy and targeted agents that generate unique imaging situations.
Collapse
Affiliation(s)
| | - P. Hilden
- Biostatistics, Memorial Sloan-Kettering Cancer Center, New York, USA
| | - B. Coiffier
- Hematology, Université Lyon-1, Lyon-Sud Charles Mérieux, Lyon, France
| | - A. Hagenbeek
- Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
| | - G. Salles
- Hematology, Université Lyon-1, Lyon-Sud Charles Mérieux, Lyon, France
| | - W. Wilson
- Lymphoid Malignancies Branch, National Cancer Institute, Bethesda, USA
| | - J. F. Seymour
- Peter MacCallum Cancer Centre and University of Melbourne, Australia
| | - K. Kelly
- Pediatrics Department, Roswell-Park Cancer Institute, Buffalo, USA
| | - J. Gribben
- Department of Haemato-Oncology, Barts Cancer Institute, London, UK
| | - M. Pfreunschuh
- Department of Internal Medicine, Universität des Saarlandes, Homburg, Germany
| | - F. Morschhauser
- Department of Hematology, Université de Lille 2, Lille, France
| | - H. Schoder
- Department of Radiology, Memorial Sloan-Kettering Cancer Center, New York
| | | | - J. Rademaker
- Department of Radiology, Memorial Sloan-Kettering Cancer Center, New York
| | - R. Advani
- Department of Oncology, Stanford University, Stanford
| | | | | | | | - L. H. Sehn
- British Columbia Cancer Agency, Vancouver, Canada
| | - A. Engert
- Department of Internal Medicine, University Hospital of Cologne, Cologne, Germany
| | | | - P.-L. Zinzani
- Department of Hematology, University of Bologna, Bologna
| | - M. Federico
- Department of Diagnostic Medicine, University of Modena, Modena, Italy
| | - M. Hutchings
- Department of Hematology, University of Copenhagen, Denmark
| | - C. Bollard
- Children’s National Health System, Washington, USA
| | - M. Trneny
- Lymphoma and Stem Cell Transplantation Program, Charles University, Prague, Czech Republic
| | | | - K. Tobinai
- Department of Hematology, National Cancer Center Hospital, Tokyo, Japan
| | - J. S. Abramson
- Massachusetts General Hospital, Center for Lymphoma, Boston
| | - N. Fowler
- U.T. M.D.Anderson Cancer Center, Houston
| | - A. Goy
- John Theurer Cancer Center, Hackensack University Medical Center, Hackensack
| | - M. Smith
- Cleveland Clinic, Cleveland, USA
| | | | - J. Kuruvilla
- Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, Canada
| | - M. Dreyling
- Medicine Clinic III, Ludwig Maximilian University, Munich, Germany
| | | | - R. F. Little
- Divisions of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, USA
| | - I. Aurer
- Department of Hematology, University Hospital Centre Zagreb, Zagreb, Croatia
| | | | | | - A. Gopal
- Fred Hutchinson Cancer Research Center, Seattle, USA
| | - S. Rule
- Haematology Department, Plymouth University, UK
| | | | - I. Kloos
- Servier, Neuilly sur Seine, France
| | - M. S. Kaminski
- University of Michigan Comprehensive Cancer Center, Ann Arbor, USA
| | - M. Meignan
- Nuclear Medicine, Hôpitaux Universitaires Henri Mondor, Créteil, France
| | - L. H. Schwartz
- Columbia University College of Physicians and Surgeons and New York Presbyterian Hospital, New York
| | - J. P. Leonard
- Weill Cornell Medicine and and New York Presbyterian Hospital, New York
| | - S. J. Schuster
- University of Pennsylvania School of Medicine, Philadelphia, USA
| | - V. E. Seshan
- Biostatistics, Memorial Sloan-Kettering Cancer Center, New York, USA
| |
Collapse
|
10
|
Huet S, Tesson B, Jais J, Feldman A, Magnano L, Thomas E, Traverse-Glehen A, Albaud B, Xerri L, Ansell S, Tarte K, Boyault S, Haioun C, Link B, Feugier P, Lopez-Guillermo A, Brice P, Hayette S, Jardin F, Offner F, Gentien D, Viari A, Campo E, Cerhan J, Salles G. GENE-EXPRESSION PROFILING PREDICTS DISEASE PROGRESSION IN FOLLICULAR LYMPHOMA. Hematol Oncol 2017. [DOI: 10.1002/hon.2437_103] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
Affiliation(s)
- S. Huet
- Laboratoire d'Hématologie; Hospices Civils de Lyon; Pierre-Bénite France
| | - B. Tesson
- Biostatistiques; Institut Carnot-Calym; Pierre-Bénite France
| | - J. Jais
- Biostatistiques; Institut Carnot-Calym; Pierre-Bénite France
| | - A.L. Feldman
- Department of Laboratory Medicine and Pathology, Mayo Clinic; Rochester USA
| | - L. Magnano
- Department of Anatomic Pathology, Hospital Clinic, IDIBAPS, Ciberonc; University of Barcelona; Barcelona Spain
| | - E. Thomas
- Plateforme de Bioinformatique 'Gilles Thomas', Synergie Lyon Cancer; Lyon France
| | - A. Traverse-Glehen
- Laboratoire d'Hématologie; Hospices Civils de Lyon; Pierre-Bénite France
| | - B. Albaud
- Translational Research Department, Genomic platform, Institut Curie; PSL Research University; Paris France
| | - L. Xerri
- Department of Bio-Pathology, Institut Paoli-Calmettes; Aix-Marseille University; Marseille; France
| | - S. Ansell
- Hematology; Mayo Clinic; Rochester USA
| | - K. Tarte
- INSERM U917; Université Rennes 1, EFS Bretagne, CHU Rennes; Rennes France
| | - S. Boyault
- Département de Recherche Translationnelle et d'Innovation, Génomique des Cancers, Centre Léon Bérard; Lyon France
| | - C. Haioun
- Unité Hémopathies Lymphoïdes; Assistance Publique-Hopitaux de Paris; Créteil France
| | - B. Link
- Department of Medicine; University of Iowa; Iowa City USA
| | - P. Feugier
- Hematology; Nancy University Hospital; Vandoeuvre-Lès-Nancy France
| | - A. Lopez-Guillermo
- Department of Anatomic Pathology, Hospital Clinic, IDIBAPS, Ciberonc; University of Barcelona; Barcelona Spain
| | - P. Brice
- Hématologie; Assistance Publique-Hopitaux de Paris; Paris France
| | - S. Hayette
- Laboratoire d'Hématologie; Hospices Civils de Lyon; Pierre-Bénite France
| | - F. Jardin
- Inserm U1245, Henri Becquerel Comprehensive Cancer Center; Rouen France
| | - F. Offner
- Hematology; Universitat Ziekenhuis Gent; Ghent Belgium
| | - D. Gentien
- Translational Research Department, Genomic platform, Institut Curie; PSL Research University; Paris France
| | - A. Viari
- Plateforme de Bioinformatique 'Gilles Thomas', Synergie Lyon Cancer; Lyon France
| | - E. Campo
- Department of Anatomic Pathology, Hospital Clinic, IDIBAPS, Ciberonc; University of Barcelona; Barcelona Spain
| | - J.R. Cerhan
- Department of Health Sciences Research; Mayo Clinic; Rochester USA
| | - G. Salles
- Service d'hématologie Marcel Bérard; CHLS, Hospices Civils de Lyon; Pierre-Bénite France
| |
Collapse
|
11
|
Lunning M, Horwitz S, Mehta-Shah N, Moskowitz A, Advani R, Beaven A, Haverkos B, Lechowicz M, Oki Y, Zain J, Ansell S. PHASE I/II STUDY OF CHOEP PLUS LENALIDOMIDE AS INITIAL THERAPY FOR PATIENTS WITH STAGE II-IV PERIPHERAL T-CELL NON-HODGKIN LYMPHOMA: PHASE I RESULTS FROM THE T-CELL CONSORTIUM. Hematol Oncol 2017. [DOI: 10.1002/hon.2439_190] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Affiliation(s)
- M. Lunning
- Hematology/Oncology; University of Nebraska Medical Center; Omaha USA
| | - S. Horwitz
- Lymphoma Service; Memorial Sloan Kettering Cancer Center; New York USA
| | | | - A. Moskowitz
- Lymphoma Service; Memorial Sloan Kettering Cancer Center; New York USA
| | - R. Advani
- Oncology; Stanford University; Palo Alto USA
| | - A. Beaven
- Hematologic Malignancies adn Cellular Therapy; Duke University; Durham USA
| | - B. Haverkos
- Oncology; University of Colorado School of Medicine; Aurora USA
| | | | - Y. Oki
- Cancer Medicine, M.D. Anderson Cancer Center`; Houston USA
| | - J. Zain
- Hematology & Hematopoietic Cell Transplantation; City of Hope, Duarte USA
| | - S. Ansell
- Oncology; Mayo Clinic; Rochester USA
| |
Collapse
|
12
|
Fanale M, Engert A, Younes A, Armand P, Ansell S, Zinzani P, Timmerman J, Collins G, Ramchandren R, Cohen J, De Boer J, Kuruvilla J, Savage K, Trneny M, Rodig S, Shipp M, Kato K, Sumbul A, Farsaci B, Santoro A. NIVOLUMAB FOR RELAPSED/REFRACTORY CLASSICAL HODGKIN LYMPHOMA AFTER AUTOLOGOUS TRANSPLANT: FULL RESULTS AFTER EXTENDED FOLLOW-UP OF THE PHASE 2 CHECKMATE 205 TRIAL. Hematol Oncol 2017. [DOI: 10.1002/hon.2437_124] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Affiliation(s)
- M. Fanale
- Department of Lymphoma/Myeloma; University of Texas MD Anderson Cancer Center; Houston USA
| | - A. Engert
- Department of Internal Medicine I; University Hospital of Cologne; Cologne Germany
| | - A. Younes
- Lymphoma Service; Memorial Sloan Kettering Cancer Center; New York USA
| | - P. Armand
- Medical Oncology; Dana-Farber Cancer Institute; Boston USA
| | - S. Ansell
- Division of Hematology; Mayo Clinic; Rochester USA
| | - P.L. Zinzani
- Institute of Hematology “L. e A. Seràgnoli; University of Bologna; Bologna Italy
| | - J.M. Timmerman
- Division of Hematology and Oncology; University of California, Los Angeles; Los Angeles USA
| | - G.P. Collins
- Oxford Cancer and Haematology Center; Churchill Hospital; Headington Oxford UK
| | - R. Ramchandren
- Department of Hematology/Oncology; Barbara Ann Karmanos Cancer Institute; Detroit USA
| | - J.B. Cohen
- Department of Hematology and Medical Oncology, Winship Cancer Institute; Emory University; Atlanta USA
| | - J.P. De Boer
- Department of Medical Oncology, Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital; Amsterdam Netherlands
| | - J. Kuruvilla
- Department of Medical Oncology and Hematology; University of Toronto and Princess Margaret Cancer Centre; Toronto Canada
| | - K.J. Savage
- Department of Medical Oncology; British Columbia Cancer Agency; Vancouver Canada
| | - M. Trneny
- Department of Hematology; Charles University in Prague and General University Hospital in Prague; Prague Czech Republic
| | - S. Rodig
- Department of Pathology; Brigham and Women's Hospital; Boston USA
| | - M. Shipp
- Center for Hematologic Oncology; Dana-Farber Cancer Institute; Boston USA
| | - K. Kato
- Global Clinical Research; Bristol-Myers Squibb; Lawrenceville USA
| | - A. Sumbul
- Global Biostatistics; Bristol-Myers Squibb; Lawrenceville USA
| | - B. Farsaci
- Oncology Biomarkers; Bristol-Myers Squibb; Lawrenceville USA
| | - A. Santoro
- Department of Medical Oncology and Hematology, Humanitas Cancer Center; Humanitas University; Rozzano Milan Italy
| |
Collapse
|
13
|
Diefenbach C, Hong F, David K, Cohen J, Roberston M, Advani R, Palmisano N, Ambinder R, Kahl B, Ansell S. SAFETY AND EFFICACY OF COMBINATION OF BRENTUXIMAB VEDOTIN AND NIVOLUMAB IN RELAPSED / REFRACTORY HODGKIN LYMPHOMA: a TRIAL OF THE ECOG-ACRIN CANCER RESEARCH GROUP (E4412). Hematol Oncol 2017. [DOI: 10.1002/hon.2437_72] [Citation(s) in RCA: 23] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Affiliation(s)
- C.S. Diefenbach
- Hematology-Oncology; NYU Perlmutter Cancer Center; New York USA
| | - F. Hong
- Biostatistics; Dana Farber Cancer Institute; Boston USA
| | - K. David
- Hematology-Oncology; Rutgers the Cancer Institute of New Jersey; New Jersey USA
| | - J. Cohen
- Oncology; Emory University; Georgia USA
| | - M. Roberston
- Hematology-Oncology; Indiana University Hospital; Bloomington USA
| | - R. Advani
- Medicine/Oncology; Stanford University Medical Center; Stanford USA
| | - N. Palmisano
- Hematology-Oncology; Penn State Milton S. Hershey Cancer Institute; Pennsylvania USA
| | - R. Ambinder
- Hematologic Malignances; Johns Hopkins Hospital; Baltimore USA
| | - B. Kahl
- Hematology and Oncology; Washington University School of Medicine in Saint Louis; Saint Louis USA
| | - S. Ansell
- Hematology-Oncology; Mayo Clinic; Rochester USA
| |
Collapse
|
14
|
Sarkozy C, Link B, Ghesquieres H, Maurer M, Nicolas-Virelizier E, Thompson C, Traverse-Glehen A, Feldman A, Allmer C, Slager S, Ansell S, Habermann T, Bachy E, Cerhan J, Salles G. CAUSE OF DEATH IN FOLLICULAR LYMPHOMA IN THE RITUXIMAB ERA: A POOLED ANALYSIS OF FRENCH AND US COHORTS. Hematol Oncol 2017. [DOI: 10.1002/hon.2437_15] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Affiliation(s)
- C. Sarkozy
- Hematology; Centre Hospitalier Lyon Sud; Pierre Bénite France
| | - B. Link
- Internal Medicine; University of Iowa Hospitals and Clinics; Iowa City USA
| | - H. Ghesquieres
- Hematology; Centre Hospitalier Lyon Sud; Pierre Bénite France
| | - M. Maurer
- Health Sciences Research; Mayo Clinic; Rochester USA
| | | | | | | | - A. Feldman
- Laboratory Medicine and Pathology, Mayo Clinic; Rochester USA
| | - C. Allmer
- Health Sciences Research; Mayo Clinic; Rochester USA
| | - S. Slager
- Health Sciences Research; Mayo Clinic; Rochester USA
| | - S. Ansell
- Medicine, Mayo Clinic; Rochester USA
| | | | - E. Bachy
- Hematology; Centre Hospitalier Lyon Sud; Pierre Bénite France
| | - J. Cerhan
- Hematology; Mayo Clinic; Rochester USA
| | - G. Salles
- Hematology; Centre Hospitalier Lyon Sud; Pierre Bénite France
| |
Collapse
|
15
|
Affiliation(s)
- V. Santoro
- European Spallation Source ERIC, SE-221 00 Lund, Sweden
| | - X.X. Cai
- European Spallation Source ERIC, SE-221 00 Lund, Sweden
- DTU Nutech, Technical University of Denmark, Roskilde, Denmark
| | - D.D. DiJulio
- European Spallation Source ERIC, SE-221 00 Lund, Sweden
- Department of Physics, Lund University, SE-221 00 Lund, Sweden
| | - S. Ansell
- European Spallation Source ERIC, SE-221 00 Lund, Sweden
| | - P.M. Bentley
- European Spallation Source ERIC, SE-221 00 Lund, Sweden
- Department of Physics and Astronomy, Uppsala University, 751 05 Uppsala, Sweden
| |
Collapse
|
16
|
Salvarani C, Brown R, Christianson T, Giannini C, Huston J, Ansell S, Hunder G. FRI0356 Primary Central Nervous System Vasculitis Associated with Lymphomas. Ann Rheum Dis 2016. [DOI: 10.1136/annrheumdis-2016-eular.5583] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
17
|
Pepin K, Ansell S, Ehman R, McGee K. TU-G-BRA-09: MR Elastography as a Predictor of Therapeutic Response: Assessment in Non-Hodgkin's Lymphoma (NHL). Med Phys 2015. [DOI: 10.1118/1.4925759] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
|
18
|
Affiliation(s)
- P. E. Mason
- Institute
of Organic Chemistry
and Biochemistry, Academy of Sciences of the Czech Republic, Flemingovo
nám. 2, 16610 Prague 6, Czech Republic
| | - S. Ansell
- Rutherford Appleton Laboratories, Chilton, Oxfordshire OX11 0QX, United Kingdom
| | - G. W. Neilson
- Department Physics, University of Bristol, Tyndall Ave., Bristol BS8 1TL, United Kingdom
| | - S. B. Rempe
- Center for Biological and
Materials Sciences, Sandia National Laboratories, Albuquerque, New Mexico 87185-1315, United States
| |
Collapse
|
19
|
Neilson GW, Ansell S, Wilson J. The Structural and Dynamic Properties of some Transition Metal Aqua Cations: Results from Neutron Scattering. ACTA ACUST UNITED AC 2014. [DOI: 10.1515/zna-1995-2-317] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
Abstract
The following paper comprises a survey of the role neutron scattering methods have played to help understand the origins of the diverse properties of electrolyte solutions which contain transition metal cations. It is seen how neutron diffraction and isotopic substitution is able to resolve the local structure around contrasting ions, such as Cr3+ , Ni2+, Fe3+ , Fe2+, Cu2+, without recourse to sophisticated modelling procedures. Quasielastic neutron scattering (QNS) provides insight into the dynamics of the protons in solution. The results enable one to distinguish between cations whose water molecules are coordinated on time scales larger than 5 x 10-9 s, shorter than 10-10s, or intermediate between those two limits. QNS also provides information on the existence of a second relatively short-lived hydration shell distinct from the bulk water.
Collapse
Affiliation(s)
- G. W. Neilson
- H. H. Wills Physics Laboratory, University of Bristol, Tyndall Avenue, Bristol BS8 1TL, United Kingdom
| | - S. Ansell
- H. H. Wills Physics Laboratory, University of Bristol, Tyndall Avenue, Bristol BS8 1TL, United Kingdom
| | - J. Wilson
- H. H. Wills Physics Laboratory, University of Bristol, Tyndall Avenue, Bristol BS8 1TL, United Kingdom
| |
Collapse
|
20
|
Ehlers SL, Bronars CA, Patten CA, Brockman T, Hughes C, Decker PA, Cerhan JR, Hogan W, Dispenzieri A, Ansell S, Ebbert J, Gastineau D. Accuracy of self-reported tobacco use status among hematopoietic SCT patients. Bone Marrow Transplant 2014; 49:961-5. [PMID: 24732958 PMCID: PMC4162628 DOI: 10.1038/bmt.2014.70] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/26/2013] [Revised: 02/20/2014] [Accepted: 02/26/2014] [Indexed: 11/21/2022]
Abstract
Tobacco use is a risk factor for adverse outcomes among Hematopoietic Stem Cell Transplant (HSCT) patients. Accurate identification of tobacco use offers a vital opportunity to treat this risk factor. The current study compared self-reported tobacco use status to serum cotinine levels among HSCT patients at time of pre-transplant evaluation. A total of 444 participants completed both assessments; 44 participants (9.9%) were classified as tobacco users with serum cotinine concentrations > 2ng/Ml versus 29 with self-report. Sensitivity and specificity of self-report were 65.9% and 100%. Positive predictive and negative predictive values were 100% and 96.4%. Comparing tobacco use documented in the medical record with cotinine, sensitivity and specificity were 51.2% and 99.2%. Factors associated with tobacco use were male gender, single relationship status, less education, and younger age. In summary, utilization of serum cotinine assays increased detection of tobacco use cases more than 50% over self-report. Results are discussed in context of translation to care, including clinical and ethical implications, and current tobacco use treatment guidelines. When cotinine assays are not available, self-report of any tobacco use in the year prior to HSCT should trigger brief advice and cessation or relapse prevention counseling.
Collapse
Affiliation(s)
- S L Ehlers
- 1] Department of Psychiatry and Psychology, Mayo Clinic College of Medicine, Rochester, MN, USA [2] Behavioral Health Research Program, Mayo Clinic College of Medicine, Rochester, MN, USA
| | - C A Bronars
- 1] Department of Psychiatry and Psychology, Mayo Clinic College of Medicine, Rochester, MN, USA [2] Behavioral Health Research Program, Mayo Clinic College of Medicine, Rochester, MN, USA
| | - C A Patten
- 1] Department of Psychiatry and Psychology, Mayo Clinic College of Medicine, Rochester, MN, USA [2] Behavioral Health Research Program, Mayo Clinic College of Medicine, Rochester, MN, USA
| | - T Brockman
- Behavioral Health Research Program, Mayo Clinic College of Medicine, Rochester, MN, USA
| | - C Hughes
- Behavioral Health Research Program, Mayo Clinic College of Medicine, Rochester, MN, USA
| | - P A Decker
- Division of Biomedical Statistics and Informatics, Mayo Clinic College of Medicine, Rochester, MN, USA
| | - J R Cerhan
- Division of Epidemiology, Mayo Clinic College of Medicine, Mayo Clinic, Rochester, MN, USA
| | - W Hogan
- Division of Hematology, Mayo Clinic College of Medicine, Rochester, MN, USA
| | - A Dispenzieri
- Division of Hematology, Mayo Clinic College of Medicine, Rochester, MN, USA
| | - S Ansell
- Division of Hematology, Mayo Clinic College of Medicine, Rochester, MN, USA
| | - J Ebbert
- 1] Nicotine Dependence Center Research Program, Mayo Clinic College of Medicine, Rochester, MN, USA [2] Department of Internal Medicine, Mayo Clinic College of Medicine, Rochester, MN, USA
| | - D Gastineau
- 1] Division of Hematology, Mayo Clinic College of Medicine, Rochester, MN, USA [2] Human Cellular Therapy Laboratory, Mayo Clinic College of Medicine, Rochester, MN, USA
| |
Collapse
|
21
|
Abbott R, Albach D, Ansell S, Arntzen JW, Baird SJE, Bierne N, Boughman J, Brelsford A, Buerkle CA, Buggs R, Butlin RK, Dieckmann U, Eroukhmanoff F, Grill A, Cahan SH, Hermansen JS, Hewitt G, Hudson AG, Jiggins C, Jones J, Keller B, Marczewski T, Mallet J, Martinez-Rodriguez P, Möst M, Mullen S, Nichols R, Nolte AW, Parisod C, Pfennig K, Rice AM, Ritchie MG, Seifert B, Smadja CM, Stelkens R, Szymura JM, Väinölä R, Wolf JBW, Zinner D. Hybridization and speciation. J Evol Biol 2013; 26:229-46. [DOI: 10.1111/j.1420-9101.2012.02599.x] [Citation(s) in RCA: 1370] [Impact Index Per Article: 124.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/18/2012] [Revised: 06/25/2012] [Accepted: 07/16/2012] [Indexed: 12/17/2022]
|
22
|
Baxter DV, Ansell S, Ferguson P, Gallmeier F, Iverson E, Kaiser H, Lu W, Muhrer G, Rinckel T, Steinbach T. Moderators at LENS: Performance and Development Research. ACTA ACUST UNITED AC 2012. [DOI: 10.1016/j.phpro.2012.03.020] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
23
|
Weersink R, Lindsay P, Clarkson R, Ansell S, Wilson G, Jaffray D. SU-E-I-190: Integration of Bioluminescence Imaging and Cone-Beam CT for Image- Guided Small Animal Irradiation. Med Phys 2011. [DOI: 10.1118/1.3611764] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
|
24
|
Clarkson R, Lindsay PE, Ansell S, Wilson G, Jelveh S, Hill RP, Jaffray DA. Characterization of image quality and image-guidance performance of a preclinical microirradiator. Med Phys 2011; 38:845-56. [PMID: 21452722 DOI: 10.1118/1.3533947] [Citation(s) in RCA: 140] [Impact Index Per Article: 10.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
Abstract
PURPOSE To assess image quality and image-guidance capabilities of a cone-beam CT based small-animal image-guided irradiation unit (micro-IGRT). METHODS A micro-IGRT system has been developed in collaboration with the authors' laboratory as a means to study the radiobiological effects of conformal radiation dose distributions in small animals. The system, the X-Rad 225Cx, consists of a 225 kVp x-ray tube and a flat-panel amorphous silicon detector mounted on a rotational C-arm gantry and is capable of both fluoroscopic x-ray and cone-beam CT imaging, as well as image-guided placement of the radiation beams. Image quality (voxel noise, modulation transfer, CT number accuracy, and geometric accuracy characteristics) was assessed using water cylinder and micro-CT test phantoms. Image guidance was tested by analyzing the dose delivered to radiochromic films fixed to BB's through the end-to-end process of imaging, targeting the center of the BB, and irradiation of the film/BB in order to compare the offset between the center of the field and the center of the BB. Image quality and geometric studies were repeated over a 5-7 month period to assess stability. RESULTS CT numbers reported were found to be linear (R2 0.998) and the noise for images of homogeneous water phantom was 30 HU at imaging doses of approximately 1 cGy (to water). The presampled MTF at 50% and 10% reached 0.64 and 1.35 mm(-1), respectively. Targeting accuracy by means of film irradiations was shown to have a mean displacement error of [deltax, deltay, deltaz] = [-0.12, -0.05, -0.02] mm, with standard deviations of [0.02, 0.20, 0.17] mm. The system has proven to be stable over time, with both the image quality and image-guidance performance being reproducible for the duration of the studies. CONCLUSIONS The micro-IGRT unit provides soft-tissue imaging of small-animal anatomy at acceptable imaging doses (< or =1 cGy). The geometric accuracy and targeting systems permit dose placement with submillimeter accuracy and precision. The system has proven itself to be stable over 2 yr of routine laboratory use (>1800 irradiations) and provides a platform for the exploration of targeted radiation effects in small-animal models.
Collapse
Affiliation(s)
- R Clarkson
- Radiation Medicine Program, Princess Margaret Hospital, 610 University Avenue, Toronto, Ontario M5G 2M9, Canada
| | | | | | | | | | | | | |
Collapse
|
25
|
Bowron DT, Soper AK, Jones K, Ansell S, Birch S, Norris J, Perrott L, Riedel D, Rhodes NJ, Wakefield SR, Botti A, Ricci MA, Grazzi F, Zoppi M. NIMROD: The Near and InterMediate Range Order Diffractometer of the ISIS second target station. Rev Sci Instrum 2010; 81:033905. [PMID: 20370190 DOI: 10.1063/1.3331655] [Citation(s) in RCA: 54] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/29/2023]
Abstract
NIMROD is the Near and InterMediate Range Order Diffractometer of the ISIS second target station. Its design is optimized for structural studies of disordered materials and liquids on a continuous length scale that extends from the atomic, upward of 30 nm, while maintaining subatomic distance resolution. This capability is achieved by matching a low and wider angle array of high efficiency neutron scintillation detectors to the broad band-pass radiation delivered by a hybrid liquid water and liquid hydrogen neutron moderator assembly. The capabilities of the instrument bridge the gap between conventional small angle neutron scattering and wide angle diffraction through the use of a common calibration procedure for the entire length scale. This allows the instrument to obtain information on nanoscale systems and processes that are quantitatively linked to the local atomic and molecular order of the materials under investigation.
Collapse
Affiliation(s)
- D T Bowron
- ISIS Facility, Rutherford Appleton Laboratory, Chilton, Didcot, Oxon OX11 0QX, United Kingdom.
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
26
|
Lindsay P, Ansell S, Jelveh S, Clarkson R, Wilson G, Hill R, Jaffray D. TH-C-BRC-06: Implementation of An Image-Guided System for Conformal Small Animal Irradiation: Characterization, QA, and Workflow. Med Phys 2009. [DOI: 10.1118/1.3182620] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
|
27
|
Advani R, Burington B, Shi X, de Vos S, Ansell S, Forero-Torres A, Ebens A, Whiting N, Dornan D. Evaluation of a gene signature to predict single agent dacetuzumab (SGN-40) activity in patients with DLBCL. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.11063] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
11063 Background: Dacetuzumab (SGN-40) is a humanized IgG1 monoclonal antibody that binds to CD40, mediates effector cell functions, and activates downstream apoptosis signaling pathways. Dacetuzumab has shown single-agent activity in relapsed/refractory DLBCL in phase I and phase II trials, with multiple objective responses and 1/3 of patients demonstrating tumor shrinkage, defined as a decrease in tumor volume (SPD) of at least 10%. We previously reported a 14-gene signature (ASH 2008 #1593) that was strongly associated with dacetuzumab sensitivity in DLBCL cell lines. Here, we report an initial evaluation of the gene signature as a classifier of patients likely to demonstrate tumor shrinkage after dacetuzumab therapy. Methods: The original 14 microarray probes were chosen for high correlation with in vitro dacetuzumab sensitivity (IC25) in 31 NHL cell line models. Matching qRT-PCR probes were developed and confirmed to correlate with the microarray probes in paired cell line samples. In this retrospective analysis, archived paraffin blocks from a 26 patient subset of the phase I and II trials, with a diagnosis of DLBCL and available tumor measurements, were assayed by qRT-PCR. Results: Overall, 42% of patients (11/26) exhibited decreased SPD of at least 10%. Of those who were marker +, 10 out of 13 (78%) had 10% or better decreases in SPD, whereas only 1 of 13 patients who were marker - demonstrated tumor shrinkage (8%). The overall accuracy for predicting tumor shrinkage was 85% (one-sided P=0.002, by permutation test). Among the 14 genes contributing to the multivariate signature, CD22 and VNN2 were the most strongly down-regulated in specimens from patients without at least a 10% decrease in SPD (P=0.14 and P=0.10, respectively), while IGF1R and CTSC were the most strongly up-regulated (P=0.05 and P=0.08, respectively). Conclusions: A 14-gene signature appears to predict tumor shrinkage in DLBCL patients receiving dacetuzumab in single-agent clinical trials (P=0.002). A larger clinical data set will be analyzed to further evaluate the correlation of this gene signature with objective clinical response rates.. [Table: see text]
Collapse
Affiliation(s)
- R. Advani
- Stanford Advanced Medicine Cancer Center, Stanford, CA; Genentech, Inc., South San Francisco, CA; David Geffen School of Medicine at UCLA, Los Angeles, CA; Mayo Clinic, Rochester, ME; University of Alabama at Birmingham, Birmingham, AL; Seattle Genetics, Inc., Bothwell, WA
| | - B. Burington
- Stanford Advanced Medicine Cancer Center, Stanford, CA; Genentech, Inc., South San Francisco, CA; David Geffen School of Medicine at UCLA, Los Angeles, CA; Mayo Clinic, Rochester, ME; University of Alabama at Birmingham, Birmingham, AL; Seattle Genetics, Inc., Bothwell, WA
| | - X. Shi
- Stanford Advanced Medicine Cancer Center, Stanford, CA; Genentech, Inc., South San Francisco, CA; David Geffen School of Medicine at UCLA, Los Angeles, CA; Mayo Clinic, Rochester, ME; University of Alabama at Birmingham, Birmingham, AL; Seattle Genetics, Inc., Bothwell, WA
| | - S. de Vos
- Stanford Advanced Medicine Cancer Center, Stanford, CA; Genentech, Inc., South San Francisco, CA; David Geffen School of Medicine at UCLA, Los Angeles, CA; Mayo Clinic, Rochester, ME; University of Alabama at Birmingham, Birmingham, AL; Seattle Genetics, Inc., Bothwell, WA
| | - S. Ansell
- Stanford Advanced Medicine Cancer Center, Stanford, CA; Genentech, Inc., South San Francisco, CA; David Geffen School of Medicine at UCLA, Los Angeles, CA; Mayo Clinic, Rochester, ME; University of Alabama at Birmingham, Birmingham, AL; Seattle Genetics, Inc., Bothwell, WA
| | - A. Forero-Torres
- Stanford Advanced Medicine Cancer Center, Stanford, CA; Genentech, Inc., South San Francisco, CA; David Geffen School of Medicine at UCLA, Los Angeles, CA; Mayo Clinic, Rochester, ME; University of Alabama at Birmingham, Birmingham, AL; Seattle Genetics, Inc., Bothwell, WA
| | - A. Ebens
- Stanford Advanced Medicine Cancer Center, Stanford, CA; Genentech, Inc., South San Francisco, CA; David Geffen School of Medicine at UCLA, Los Angeles, CA; Mayo Clinic, Rochester, ME; University of Alabama at Birmingham, Birmingham, AL; Seattle Genetics, Inc., Bothwell, WA
| | - N. Whiting
- Stanford Advanced Medicine Cancer Center, Stanford, CA; Genentech, Inc., South San Francisco, CA; David Geffen School of Medicine at UCLA, Los Angeles, CA; Mayo Clinic, Rochester, ME; University of Alabama at Birmingham, Birmingham, AL; Seattle Genetics, Inc., Bothwell, WA
| | - D. Dornan
- Stanford Advanced Medicine Cancer Center, Stanford, CA; Genentech, Inc., South San Francisco, CA; David Geffen School of Medicine at UCLA, Los Angeles, CA; Mayo Clinic, Rochester, ME; University of Alabama at Birmingham, Birmingham, AL; Seattle Genetics, Inc., Bothwell, WA
| |
Collapse
|
28
|
Lindsay P, Ansell S, Moseley D, Jelveh S, Hill R, Jaffray D. SU-GG-J-70: Development of An Image-Guided Conformal Small Animal Irradiation Platform. Med Phys 2008. [DOI: 10.1118/1.2961620] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
|
29
|
Daly M, Siewerdsen J, Moseley D, Cho Y, Ansell S, Wilson G, Jaffray D. TH-D-L100J-08: Imaging Performance of a Mobile Cone-Beam CT C-Arm for Image-Guided Interventions. Med Phys 2007. [DOI: 10.1118/1.2761698] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
|
30
|
Ansell S, Barnes AC, Mason PE, Neilson GW, Ramos S. X-ray and neutron scattering studies of the hydration structure of alkali ions in concentrated aqueous solutions. Biophys Chem 2006; 124:171-9. [PMID: 16815625 DOI: 10.1016/j.bpc.2006.04.018] [Citation(s) in RCA: 88] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/20/2005] [Revised: 04/28/2006] [Accepted: 04/29/2006] [Indexed: 11/23/2022]
Abstract
The presence of ions in water provides a rich and varied environment in which many natural processes occur with important consequences in biology, geology and chemistry. This article will focus on the structural properties of ions in water and it will be shown how the 'difference' methods of neutron diffraction with isotopic substitution (NDIS) and anomalous X-ray diffraction (AXD) can be used to obtain direct information regarding the radial pair distribution functions of many cations and anions in solution. This information can subsequently be used to calculate coordination numbers and to determine ion-water conformation in great detail. As well as enabling comparisons to be made amongst ions in particular groups in the periodic table, such information can also be contrasted with results provided by molecular dynamics (MD) simulation techniques. To illustrate the power of these 'difference' methods, reference will be made to the alkali group of ions, all of which have been successfully investigated by the above methods, with the exception of the radioactive element francium. Additional comments will be made on how NDIS measurements are currently being combined with MD simulations to determine the structure around complex ions and molecules, many of which are common in biological systems.
Collapse
Affiliation(s)
- S Ansell
- ISIS Division, Rutherford Appleton Laboratory, Chilton, Didcot, OX11 0QX, UK
| | | | | | | | | |
Collapse
|
31
|
Mason PE, Ansell S, Neilson GW. Neutron diffraction studies of electrolytes in null water: a direct determination of the first hydration zone of ions. J Phys Condens Matter 2006; 18:8437-8447. [PMID: 21690899 DOI: 10.1088/0953-8984/18/37/004] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/30/2023]
Abstract
A method of neutron diffraction is described which enables the first hydration zone of small cations to be investigated at atomic resolution. It is shown that the cation structures of aqueous electrolyte solutions dissolved in a 'null' mixture of water (H(2)O) and heavy water (D(2)O), can be calculated directly from the neutron scattering patterns. The hitherto unresolved structure around Na(+) is used to illustrate the power of this method, the accuracy of which is discussed formally with reference to standard nickel chloride solutions. Possible applications to a variety of other systems and at different thermodynamic states are proposed.
Collapse
Affiliation(s)
- P E Mason
- Department of Food Science, Cornell University, Ithaca, NY, USA
| | | | | |
Collapse
|
32
|
Jaffray D, Moseley D, Chow J, Kim S, Ansell S, Wilson G, Chiarot C. WE-D-330A-09: An Image-Guided Irradiator for Pre-Clinical Radiation Therapy Studies. Med Phys 2006. [DOI: 10.1118/1.2241750] [Citation(s) in RCA: 16] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
|
33
|
Kumar S, Lacy M, Dispenzieri A, Hayman S, Hogan W, Poratta L, Elliot M, Ansell S, Johnston P, Micallef I, Inwards D, Gastineau D, Litzow M, Gertz M. Autologous stem cell transplantation for multiple myeloma in patients over 70 years: A matched comparison with patients under 65 years. Biol Blood Marrow Transplant 2006. [DOI: 10.1016/j.bbmt.2005.11.350] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
34
|
Gill P, Galanis E, Buckner J, Christianson T, Anderson P, Ansell S, Litzow M. High dose chemotherapy (HDC) with autologous stem cell transplantation (ASCT) in adults with relapsed CNS embryonal tumors. J Clin Oncol 2005. [DOI: 10.1200/jco.2005.23.16_suppl.1525] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- P. Gill
- Mayo Clinic Coll of Medicine, Rochester, MN
| | - E. Galanis
- Mayo Clinic Coll of Medicine, Rochester, MN
| | - J. Buckner
- Mayo Clinic Coll of Medicine, Rochester, MN
| | | | | | - S. Ansell
- Mayo Clinic Coll of Medicine, Rochester, MN
| | - M. Litzow
- Mayo Clinic Coll of Medicine, Rochester, MN
| |
Collapse
|
35
|
Ambegia E, Ansell S, Cullis P, Heyes J, Palmer L, MacLachlan I. Stabilized plasmid-lipid particles containing PEG-diacylglycerols exhibit extended circulation lifetimes and tumor selective gene expression. Biochim Biophys Acta 2005; 1669:155-63. [PMID: 15893518 DOI: 10.1016/j.bbamem.2005.02.001] [Citation(s) in RCA: 139] [Impact Index Per Article: 7.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Received: 12/08/2004] [Revised: 02/01/2005] [Accepted: 02/02/2005] [Indexed: 11/19/2022]
Abstract
Stabilized plasmid lipid particles (SPLP) consist of a single copy of DNA surrounded by a lipid bilayer. The particles are small ( approximately 100 nm), stable, monodisperse and have a low surface charge. A diffusible polyethylene glycol (PEG) coating attached to a lipid anchor is critical to the SPLP's functionality. The PEG-lipid exchanges out of the bilayer at a rate determined by the size of the lipid anchor. Here we show that SPLP can be prepared using a series of PEG-diacylglycerol lipids (PEG-S-DAGs). SPLP were prepared incorporating PEG-dimyristoylglycerol (C14), PEG-dipalmitoylglycerol (C16) or PEG-distearoylglycerol (C18) and the rate of PEG-lipid diffusion from the bi-layer determined using a FRET assay. SPLP pharmacokinetics confirm a correlation between the stability of the PEG-lipid component and circulation lifetime. PEG-S-DAGs with longer lipid anchors yield more stable SPLP particles with longer circulation half-lives yielding an increase in tumor delivery and gene expression. PEG-distearoylglycerol (C18) containing SPLP bypass so-called 'first pass' organs, including the lung, and elicit levels of gene expression in distal tumor tissue 100- to 1000-fold greater than that observed in any other tissue. The incorporation of PEG-S-DAG in SPLP confirms that small size, low surface charge and extended circulation lifetimes are prerequisite to the accumulation and tumor selective expression of plasmid DNA following systemic administration.
Collapse
Affiliation(s)
- E Ambegia
- Protiva Biotherapeutics Inc., 100-3480 Gilmore Way, Burnaby, BC, Canada V5G 4Y1
| | | | | | | | | | | |
Collapse
|
36
|
Ansell S, Neilson GW. EXAFS studies of structural changes in fragile glasses of zinc nitrate and nickel nitrate hydrates. Biophys Chem 2004; 107:229-41. [PMID: 14967238 DOI: 10.1016/j.bpc.2003.09.015] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/16/2002] [Revised: 09/10/2003] [Accepted: 09/16/2003] [Indexed: 11/20/2022]
Abstract
The ionic structures of aqueous solutions of two sets of transition metal nitrates have been studied in the liquid and glass states by EXAFS spectroscopy. Experiments were carried out on Zn(NO3)2.xH2O, with x=2, 6, 12 and NiNO.9HO over the temperature range 30<T(K)<250. The glass transition regime was monitored by means of an in-situ DSC probe. The EXAFS data were analysed by recently developed Monte Carlo procedures, enabling a discussion of the glass structure in terms of pairwise and higher order correlations. Results for the zinc nitrate hydrates show complex behaviour depending on the concentration. This behaviour is explained in terms of first hydration shell stability and NO3- penetration. This result contrasts with that for the equivalent correlation in nickel nitrate, and is taken as evidence for a more extensive free energy landscape of zinc nitrate hydrates. The results are also consistent with the known hydration properties of Zn2+ and Ni2+, and help explain why Zn2+ is biologically active in solution.
Collapse
Affiliation(s)
- S Ansell
- ISIS Division, Rutherford Appleton Laboratory, Chilton, Didcot, Oxon OX11 0QX, UK.
| | | |
Collapse
|
37
|
|
38
|
Song LY, Ahkong QF, Rong Q, Wang Z, Ansell S, Hope MJ, Mui B. Characterization of the inhibitory effect of PEG-lipid conjugates on the intracellular delivery of plasmid and antisense DNA mediated by cationic lipid liposomes. Biochim Biophys Acta 2002; 1558:1-13. [PMID: 11750259 DOI: 10.1016/s0005-2736(01)00399-6] [Citation(s) in RCA: 155] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
Poly(ethylene glycol)-lipid (PEG-lipid) conjugates are widely used in the field of liposomal drug delivery to provide a polymer coat that can confer favorable pharmacokinetic characteristics on particles in the circulation. More recently these lipids have been employed as an essential component in the self-assembly of cationic and neutral lipids with polynucleic acids to form small, stable lipid/DNA complexes that exhibit long circulation times in vivo and accumulate at sites of disease. However, the presence of a steric barrier lipid might be expected to inhibit the transfection activity of lipid/DNA complexes by reducing particle-membrane contact. In this study we examine what effect varying the size of the hydrophobic anchor and hydrophilic head group of PEG-lipids has on both gene and antisense delivery into cells in culture. Lipid/DNA complexes were made using unilamellar vesicles composed of 5 mole% PEG-lipids in combination with equimolar dioleoylphosphatidylethanolamine and the cationic lipid dioleyldimethylammonium chloride. Using HeLa and HepG2 cells we show that under the conditions employed PEG-lipids had a minimal effect on the binding and subsequent endocytosis of lipid/DNA complexes but they severely inhibited active gene transfer and the endosomal release of antisense oligodeoxynucleotides into the cytoplasm. Decreasing the size of the hydrophobic anchor or the size of the grafted hydrophilic PEG moiety enhanced DNA transfer by the complexes.
Collapse
Affiliation(s)
- L Y Song
- Inex Pharmaceuticals Corp., 100-8900 Glenlyon Parkway, Glenlyon Business Park, V5J 5J8, Burnaby, BC, Canada
| | | | | | | | | | | | | |
Collapse
|
39
|
Filipponi A, Di Cicco A, De Panfilis S, Trapananti A, Itiè JP, Borowski M, Ansell S. Investigation of undercooled liquid metals using XAFS, temperature scans and diffraction. J Synchrotron Radiat 2001; 8:81-86. [PMID: 11512940 DOI: 10.1107/s0909049500019300] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/26/2000] [Accepted: 11/30/2000] [Indexed: 05/23/2023]
Abstract
Novel techniques and the experimental station for experiments on condensed matter under extreme conditions that have been developed at the BM29 beamline of the European Synchrotron Radiation Facility (ESRF) are described. The experimental setup includes facilities to collect high-quality extended X-ray absorption fine structure (EXAFS) spectra, to perform controlled temperature scans while monitoring the sample absorption for the direct detection of phase transitions, and to collect high-resolution energy-scanning X-ray diffraction (ESXD) data, with recent enhancements through the installation of a two-channel collimator detector system. Facilities for X-ray absorption temperature scans, introduced five years ago, are now exploited for a wide variety of purposes. A method for the measurement of the nucleation rate in undercooled liquids has been proposed recently. All these advances in the experimental setup and techniques, combined with a simple but rigorous X-ray absorption fine structure (XAFS) data analysis scheme for disordered matter, have contributed to make feasible challenging experiments on undercooled liquid matter that were not even conceivable only a few years ago. An example of the application of these methods to undercooled liquid indium (In) is presented.
Collapse
Affiliation(s)
- A Filipponi
- Dipartimento di Fisica, Università dell' Aquila Via Vetoio, Italy.
| | | | | | | | | | | | | |
Collapse
|
40
|
Abstract
The pH-dependent fusion properties of large unilamellar vesicles (LUVs) composed of binary mixtures of anionic and cationic lipids have been investigated. It is shown that stable LUVs can be prepared from the ionizable anionic lipid cholesteryl hemisuccinate (CHEMS) and the permanently charged cationic lipid N,N-dioleoyl-N, N-dimethylammonium chloride (DODAC) at neutral pH values and that these LUVs undergo fusion as the pH is reduced. The critical pH at which fusion was observed (pH(f)) was dependent on the cationic lipid-to-anionic lipid ratio. LUVs prepared from DODAC/CHEMS mixtures at molar ratios of 0 to 0.85 resulted in vesicles with pH(f) values that ranged from pH 4.0 to 6.7, respectively. This behavior is consistent with a model in which fusion occurs at pH values such that the DODAC/CHEMS LUV surface charge is zero. Related behavior was observed for LUVs composed of the ionizable cationic lipid 3alpha-[N-(N',N'-dimethylaminoethane)-carbamoyl] cholesterol hydrochloride (DC-Chol) and the acidic lipid dioleoylphosphatidic acid (DOPA). Freeze-fracture and (31)P NMR evidence is presented which indicates that pH-dependent fusion results from a preference of mixtures of cationic and anionic lipid for "inverted" nonbilayer lipid phases under conditions where the surface charge is zero. It is concluded that tunable pH-sensitive LUVs composed of cationic and anionic lipids may be of utility for drug delivery applications. It is also suggested that the ability of cationic lipids to adopt inverted nonbilayer structures in combination with anionic lipids may be related to the ability of cationic lipids to facilitate the intracellular delivery of macromolecules.
Collapse
Affiliation(s)
- I M Hafez
- Department of Biochemistry and Molecular Biology, University of British Columbia, Vancouver, British Columbia V6T 1Z3.
| | | | | |
Collapse
|
41
|
Abstract
The total structure factor S(Q) and the radial distribution function G(r) of liquid Y3Al5O12 (YAG) were measured at 1770-2230 K by x-ray scattering from samples under containerless conditions in Ar and O2. Nominal coordination numbers are 4 for Al3+ and 6 for Y3+ ions. The G(r) has peaks at r approximately 1.8 A for Al-O, r approximately 2. 25 A for Y-O, and r approximately 3.3-3.6 A assigned to metal ions in adjacent AlO5-4 and YO9-6 polyhedral ions. Relative to the pure oxides, G(r) for molten YAG has smaller half-widths for the Al-O and Y-O peaks, and an increased sensitivity to temperature and the ambient gas composition.
Collapse
Affiliation(s)
- JK Weber
- Containerless Research, Inc., Evanston, Illinois 60201, USA
| | | | | | | | | |
Collapse
|
42
|
|
43
|
Johnson JA, Saboungi ML, Price DL, Ansell S, Russell TP, Halley JW, Nielsen B. Atomic structure of solid and liquid polyethylene oxide. J Chem Phys 1998. [DOI: 10.1063/1.477352] [Citation(s) in RCA: 49] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
44
|
Hope MJ, Mui B, Ansell S, Ahkong QF. Cationic lipids, phosphatidylethanolamine and the intracellular delivery of polymeric, nucleic acid-based drugs (review). Mol Membr Biol 1998; 15:1-14. [PMID: 9595549 DOI: 10.3109/09687689809027512] [Citation(s) in RCA: 91] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
Polymeric, nucleic acid drugs must be protected from endogenous nucleases and delivered to target cell nuclei in order to maximize their activity. Constructs expressing therapeutic genes, antisense oligonucleotides and ribozymes can be delivered into cells by viral vectors, but concerns over safety and clinical utility have led to research into the development of alternative, non-viral delivery systems. Antisense and ribozyme drug development has focused upon modifications to the natural oligonucleotide chemistry which make the molecules resistant to nuclease degradation. These novel oligonucleotides cannot be generated by transgenes and must be administered in similar fashion to conventional drugs. However, oligonucleotides cannot cross membranes by passive diffusion and intracellular delivery for these drugs is very inefficient. Here we review the recent advances in forming lipid-DNA particles designed to mimic viral delivery of DNA. Most evidence now supports the hypothesis that lipid-DNA drugs enter target cells by endocytosis and disrupt the endosomal membrane, releasing nucleic acid into the cytoplasm. The mechanisms of particle formation and endosome disruption are not well understood. Cationic lipids are employed to provide an electrostatic interaction between the lipid carrier and polyanionic nucleic acids, and they are critical for efficient packaging of the drugs into a form suitable for systemic administration. However, their role in endosome disruption and other aspects of successful delivery leading to gene expression or inhibition of mRNA translation are less clear. We discuss the propensity of lipid-nucleic acid particles to undergo lipid mixing and fusion with adjacent membranes, and how phosphatidylethanolamine and other lipids may act as factors capable of disrupting bilayer structure and the endosomal pathway. Finally, we consider the challenges that remain in bringing nucleic acid based drugs into the realm of clinical reality.
Collapse
Affiliation(s)
- M J Hope
- Inex Pharmaceuticals Corporation, Burnaby, B.C., Canada
| | | | | | | |
Collapse
|
45
|
|
46
|
Affiliation(s)
- G Falkson
- Department of Medical Oncology, University of Pretoria, Republic of South Africa
| | | |
Collapse
|
47
|
Ansell S. Careers: plastic surgery nursing. More than hard graft. Nurs Mirror 1982; 154:58. [PMID: 6919960] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/22/2023]
|
48
|
Critchley DR, Streuli CH, Kellie S, Ansell S, Patel B. Characterization of the cholera toxin receptor on Balb/c 3T3 cells as a ganglioside similar to, or identical with, ganglioside GM1. No evidence for galactoproteins with receptor activity. Biochem J 1982; 204:209-19. [PMID: 7052064 PMCID: PMC1158335 DOI: 10.1042/bj2040209] [Citation(s) in RCA: 42] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/23/2023]
Abstract
Balb/c 3T3 cells contain a large number [(0.8-1.6) x 10(6)] of high-affinity (half-maximal binding at 0.2 nM) binding sites for cholera toxin that are resistant to proteolysis, but are quantitatively extracted with chloroform/methanol. The following evidence rigorously establishes that the receptor is a ganglioside similar to, or identical with, ganglioside GM1 by the galactose oxidase/NaB3H4 technique on intact cells was inhibited by cholera toxin. (2) Ganglioside GM1 was specifically adsorbed from Nonidet P40 extracts of both surface- (galactose oxidase/NaB3H4 technique) and metabolically ([1-14C]palmitate) labelled cells in the presence of cholera toxin, anti-toxin and Staphylococcus aureus. (3) Ganglioside GM1 was the only ganglioside labelled when total cellular gangliosides separated on silica-gel sheets were overlayed with 125I-labelled cholera toxin, although GM3 and GD1a were the major gangliosides present. In contrast no evidence for a galactoprotein with receptor activity was obtained. Cholera toxin did not protect the terminal galactose residues of cell-surface glycoproteins from labelling by the galactose oxidase/NaB3H4 technique. No toxin-binding proteins could be identified in Nonidet P40 extracts of [35S]-methionine-labelled cells by immunochemical means. After sodium dodecyl sulphate/polyacrylamide-gel electrophoresis none of the major cellular galactoproteins identified by overlaying gels with 125I-labelled ricin were able to bind 125I-labelled cholera toxin. It is concluded that the cholera toxin receptor on Balb/c 3T3 cells is exclusively ganglioside GM1 (or a related species), and that cholera toxin can therefore be used to probe the function and organisation of gangliosides in these cells as previously outlined [Critchley, Ansell, Perkins, Dilks & Ingram (1979) J. Supramol. Struct. 12, 273-291].
Collapse
|
49
|
|
50
|
Critchley DR, Ansell S, Perkins R, Dilks S, Ingram J. Isolation of cholera toxin receptors from a mouse fibroblast and lymphoid cell line by immune precipitation. J Supramol Struct 1979; 12:273-91. [PMID: 544939 DOI: 10.1002/jss.400120211] [Citation(s) in RCA: 18] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/23/2022]
Abstract
Cholera toxin receptors have been isolated from both a mouse fibroblast (Balbc/3T3) and mouse lymphoid cell line labeled by the galactose oxidase borotritiide technique. Tritiated receptor-toxin complexes solubilized in NP40 were isolated by addition of toxin antibody followed by a protein A-containing strain of Staphylococcus aureus. In both cell types by far the major species of toxin receptor isolated was ganglioside in nature, although galactoproteins were also present in the immune complexes. Whether the galactoproteins form part of a toxin-receptor complex or are artifacts of the isolation procedure is presently unclear. The relative specificity of cholera toxin for a carbohydrate sequence in a glycolipid suggests that the toxin might prove a useful tool in establishing the function and organization of glycolipids in membranes. For example, interaction of cholera toxin with the mouse lymphoid cell line was shown to result in patching and capping of bound toxin, raising the possibility that the glycolipid receptor interacts indirectly with cytoskeletal elements. Cholera toxin might also be used to select for mutant fibroblasts lacking the toxin receptor and therefore having an altered glycolipid profile. Such mutants might prove useful in establishing the relationship (if any) between modified glycolipid pattern and other aspects of the transformed phenotype. Attempts to isolate mutants, based on the expectation that growth of cells containing the toxin receptor would be inhibited by the increase in cAMP levels normally induced by cholera toxin, proved unsuccessful. Cholera toxin failed to inhibit significantly the growth of either Balbc or Swiss 3T3 mouse fibroblasts although it markedly elevated cAMP levels.
Collapse
|